Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Chesapeake Urology Associates

Neither a doctor nor a teaching hospital

Research payments

$2,554,114

1,427 payments

Through program year 2025, Chesapeake Urology Associates is reported as receiving $2,554,114 in research payments, across 1,427 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $79,760 110
2024 Research $109,194 97
2023 Research $174,173 124
2022 Research $219,135 305
2021 Research $747,266 318
2020 Research $515,415 232
2019 Research $709,171 241

Breakdown

Who paid Research payments · program years 2019–2025
  1. Blue Earth Diagnostics Limited $442,043 25 payments
  2. Boston Scientific Corporation $385,705 27 payments
  3. Dendreon Pharmaceuticals LLC $320,690 48 payments
  4. Pfizer Inc. $278,165 363 payments
  5. Astellas Pharma Global Development $270,574 79 payments
  6. Medivation Inc. $252,356 409 payments
  7. Janssen Research & Development, LLC $185,127 167 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $134,793 46 payments
  9. Axonics Modulation Technologies, Inc. $101,358 201 payments
  10. Myovant Sciences Inc. $48,787 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3 Randomized Efficacy and Safety Study of Enzalutamide Plus Leuprolide Enzalutamide Monotherapy and Placebo Plus Leuprolide in Men With Highrisk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy $528,571 767 payments
  2. Rezum XL $360,430 16 payments
  3. A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) PET Ligand in Men With Suspected Prostate Cancer Recurrence Based on Elevated PSA Following Prior Therapy. $240,747 8 payments
  4. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer (Provent) $129,697 17 payments
  5. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer Provent $127,040 9 payments
  6. A Prospective, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) Positron Emission Tomography (PET) Ligand in Men With Newly Diagnosed Prostate Cancer $118,721 8 payments
  7. A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) $102,182 23 payments
  8. Artistry $95,038 198 payments
  9. A Multinational, Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) $65,375 17 payments
  10. A Randomized Phase 3, Open-Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer $63,952 22 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record